Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

In a report released on February 1, Casey Woodring from J.P. Morgan maintained a Hold rating on Charles River Labs (CRL – Research Report), ...

Read here for an analysis of Charles River's (CRL) strong financial performance with high ROE and decreasing liabilities, indicating future capital deployment.

Complete response letter hurdles overcome and U.S. FDA clearance in hand, Axsome Therapeutics Inc. will disclose pricing in about four months, closer to the launch of Symbravo to treat adult migraine ...

Flagship Harbor Advisors LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) ...

Bank of America Securities analyst Juan Avendano reiterated a Hold rating on Charles River Labs (CRL – Research Report) today and set a price ...

Atomi Financial Group Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...